KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Expenses (2016 - 2025)

Novavax has reported Operating Expenses over the past 16 years, most recently at $132.9 million for Q4 2025.

  • Quarterly results put Operating Expenses at $132.9 million for Q4 2025, down 39.42% from a year ago — trailing twelve months through Dec 2025 was $670.7 million (down 27.97% YoY), and the annual figure for FY2025 was $670.7 million, down 27.97%.
  • Operating Expenses for Q4 2025 was $132.9 million at Novavax, down from $248.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for NVAX hit a ceiling of $1.0 billion in Q4 2021 and a floor of $132.9 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $381.3 million (2023), compared with a mean of $430.6 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 2396.24% in 2021 and later plummeted 63.72% in 2023.
  • Novavax's Operating Expenses stood at $1.0 billion in 2021, then crashed by 42.58% to $601.3 million in 2022, then decreased by 21.02% to $474.9 million in 2023, then crashed by 53.8% to $219.4 million in 2024, then plummeted by 39.42% to $132.9 million in 2025.
  • The last three reported values for Operating Expenses were $132.9 million (Q4 2025), $248.5 million (Q3 2025), and $138.2 million (Q2 2025) per Business Quant data.